Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Normal saline Clear all
Terminated Phase 2 Interventional Results available

Pegylated Interferon Lambda Treatment for COVID-19

NCT04343976
View directory record Official record
Conditions
COVID-19, COVID
Interventions
Pegylated interferon lambda
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 3, 2026, 11:23 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation

NCT01917006
View directory record Official record
Conditions
Premature Ejaculation
Interventions
OnabotulinumtoxinA, Normal Saline
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
San Diego, California • Torrance, California • Middlebury, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Not applicable Interventional Results available

Convergence Insufficiency Treatment Study (CITS)

NCT01515943
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
Active home-based computer vergence/accommodative therapy, Near target push-ups, Placebo home-based computer vergence/accommodative therapy, Placebo yoked prism flippers
Other · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
9 Years to 17 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Cranberry TWP, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 3, 2026, 11:23 PM EDT
Not yet recruiting Not applicable Interventional

Quadratus Lumborum Versus Placebo in Open Ventral Hernia Repair

NCT06953635
View directory record Official record
Conditions
Hernia, Ventral, Pain Management
Interventions
Quadratus Lumborum (QL) Block, Placebo
Procedure
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 3, 2026, 11:23 PM EDT
Recruiting Phase 2 Interventional

Motivation for IV Alcohol Self-Administration in Humans

NCT06494891
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Intravenous Alcohol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 3, 2026, 11:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

NCT02415842
View directory record Official record
Conditions
Immunologic Tests
Interventions
Serum samples
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 64 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

NCT01505088
View directory record Official record
Conditions
Anterior Uveitis
Interventions
40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution, Placebo Eyedrops
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

NCT04317040
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Efprezimod alfa, Placebo
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children

NCT02707523
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Azithromycin 10 mg, Azithromycin 20mg, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 16 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Early Phase 1 Interventional

Intraoperative Ketamine for Patients Undergoing Total Joint Arthroplasty

NCT04437888
View directory record Official record
Conditions
Pain, Postoperative, Arthroplasty Complications
Interventions
Ketamine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 4 Interventional Results available

Early Versus Routine Caffeine Administration in Extremely Preterm Neonates

NCT01783561
View directory record Official record
Conditions
Caffeine
Interventions
Caffeine
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease

NCT01247090
View directory record Official record
Conditions
Hypertension, End Stage Renal Disease
Interventions
Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 3, 2026, 11:23 PM EDT
Terminated Not applicable Interventional

The Effect of Systemic or Perineural Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine

NCT01495624
View directory record Official record
Conditions
Duration of Interscalene Block
Interventions
ropivacaine plus dexamethasone anesthetic, ropivacaine plus saline plus dexamethasone anesthetic
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Early Phase 1 Interventional

Effect of Enamel Matrix Proteins on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients

NCT02972788
View directory record Official record
Conditions
Periodontal Bone Loss
Interventions
Enamel Matrix Proteins Derivative, Saline
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

NCT05226923
View directory record Official record
Conditions
Bacterial Infections
Interventions
KSP-1007, Placebo:0.9% sodium chloride, Meropenem
Drug · Other
Lead sponsor
Sumitovant Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 3, 2026, 11:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism

NCT01893359
View directory record Official record
Conditions
Hyperopia, Hyperopic Astigmatism
Interventions
riboflavin ophthalmic solution, 0% dextran, UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA), UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off), Laser-assisted in situ keratomileusis
Drug · Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
San Diego, California • Waltham, Massachusetts • Teaneck, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 3, 2026, 11:23 PM EDT
Terminated Not applicable Interventional Results available

Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies

NCT04764396
View directory record Official record
Conditions
Pancreas, Mass Lesion
Interventions
Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe), Saline
Combination Product · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma

NCT02749968
View directory record Official record
Conditions
Blunt Chest Wall Trauma, Rib Fracture, Sternal Fracture
Interventions
Liposomal bupivacaine, 0.9% sodium chloride
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 4 Interventional Results available

Steroids in Bilateral Total Knee Replacement

NCT01399268
View directory record Official record
Conditions
Postoperative Inflammatory Response
Interventions
Hydrocortisone, Saline
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 4 Interventional Results available

Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study

NCT02806024
View directory record Official record
Conditions
Placenta Accreta, Postpartum Hemorrhage, Cesarean Section, Tranexamic Acid
Interventions
Tranexamic Acid, Placebo Drug
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures

NCT00937924
View directory record Official record
Conditions
Endoscopic Ultrasound (EUS), Endoscopic Retrograde Cholangiopancreatography (ERCP)
Interventions
Meperidine, Midazolam, Diphenhydramine, Promethazine
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Sep 3, 2026, 11:23 PM EDT
Terminated Phase 2 Interventional Results available

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

NCT01911273
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
PF-03446962, Best Supportive Care, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 3, 2026, 11:23 PM EDT
Terminated Phase 4 Interventional Results available

Angiotensin II for Distributive Shock

NCT04904562
View directory record Official record
Conditions
Distributive Shock
Interventions
Angiotensin II, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 11:23 PM EDT